This study first proposed the “DNA methylation-TAGLN2 succinylation-immune/metabolic” regulatory axis, providing new ideas and potential targets for the epigenetic mechanism and precise treatment of PAH. This evidence concerns the gene TAGLN2 and pulmonary arterial hypertension.